| Key takeaways |
| ▪ GLP-1 stands for glucagon-like peptide-1, a hormone your gut already releases after you eat. These medicines are engineered copies of it. ▪ The class is not one drug. Members differ by which receptors they act on, whether they are taken daily or weekly, whether they are injected or swallowed, and what they are approved to treat. ▪ The published trial evidence supports reductions of up to 20% of body weight. The spread between individuals on identical treatment is wide. ▪ Nausea, vomiting, constipation and reflux are the common effects and cluster in the early weeks. Serious effects exist and are rare. ▪ In a systematic review of the trials behind these medicines, 79% of participants were Western and Asians made up 13%, with no separate reporting for South Asians. ▪ Indian thresholds sit lower than the Western ones quoted in most articles: increased adiposity from a BMI of 23, obesity from 25, and a waist above 90 cm in men or 80 cm in women. |
GLP-1 medicines are prescription drugs that copy a gut hormone your body makes naturally. They slow how fast the stomach empties, quiets appetite signalling in the brain, and sharpens the insulin response to food. They are not interchangeable with one another. What separates them is receptor targeting, dosing rhythm, approved indication, and the strength of the evidence that they protect the heart.
This piece walks through each of those differences, then does something most coverage of this topic avoids: it looks at who was actually studied.
What does GLP-1 actually stand for, and why does your body make it?
GLP-1 is short for glucagon-like peptide-1. It is an incretin hormone, released by cells in your small intestine within minutes of food arriving. Its job is to tell the rest of your body that you have eaten.
That message does several things at once. The pancreas releases insulin, but only when glucose is high, which is why the hormone lowers sugar without driving it dangerously low. Glucagon, the hormone that pushes stored sugar out of the liver, is suppressed. The stomach empties more slowly. And appetite centres in the brain register fullness.
Your own GLP-1 is broken down within a couple of minutes. The medicines are built to resist that breakdown, which is the whole trick. They hold the after-eating signal open for hours or days instead of minutes.
So how do these medicines work once they are consumed?
The same four levers, sustained. Slower gastric emptying means a normal-sized meal sits longer and registers as more food. Appetite signalling shifts, so the mental pull toward the second helping weakens rather than being resisted. Insulin release improves in response to glucose. Glucagon output falls.
The practical consequence is that people eat less without the constant negotiation that usually accompanies eating less. That is the mechanism, and it is also the limit of the mechanism. Nothing here burns fat directly, and nothing here builds muscle.
This matters for how the medicines are used. Every regulatory approval in this class positions them as an addition to changes in eating and activity, not a replacement for them.
Are all GLP-1 medicines the same medicine?
No, and the differences are not cosmetic.
Most members of the class act on the GLP-1 receptor alone. Semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide all belong here. Within that group, the meaningful separations are how long each one lasts in the body, which determines daily against weekly dosing, and how much weight reduction each achieves.
Tirzepatide is different. It activates the GLP-1 receptor and also the GIP receptor, a second incretin pathway. Strictly speaking it is a dual agonist rather than a GLP-1 medicine, though almost everyone files it under the same heading. In the SURMOUNT-1 trial the investigators noted that GIP receptors and GLP-1 receptors are expressed in overlapping but not identical parts of the brain, which is the leading hypothesis for why hitting both does more than hitting one.
One more split people find confusing. A single molecule can carry more than one brand name, because the brand is tied to the approved indication rather than to the chemistry. Semaglutide is sold under one name for type 2 diabetes, another for weight management, and a third as a tablet. Same molecule, different labels, different approved uses. The same pattern applies to liraglutide and to tirzepatide.
Which one produces the most weight reduction?
There is exactly one head-to-head trial worth building an answer on. SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes to either the dual-receptor medicine or the single-hormone one, and followed them for 72 weeks. The dual-receptor arm reached greater reductions in both body weight and waist circumference.
The trial was open-label, meaning everyone knew which medicine they were on. Everyone enrolled was free of type 2 diabetes, so the finding does not transfer cleanly to someone managing blood sugar. Within every arm of every trial in this class, some participants lost a great deal and some lost very little on identical treatment.
Across the class, the published evidence supports reductions of up to 20% of body weight. Treating that as the number you will hit is a misreading of what a trial ceiling means.
The older members of the class, the daily and earlier weekly options, are generally less potent for weight reduction than the two newest. Less potent is not the same as obsolete, and the next section explains why.
Which of them has actually been proven to protect your heart?
This is where the ranking changes, and where most coverage collapses two very different things into one.
Four molecules have placebo-controlled evidence of reduced cardiovascular events. Liraglutide showed it in LEADER . Injectable semaglutide showed it in SUSTAIN-6 and then, more importantly for anyone without diabetes, in SELECT , where 17,604 adults with existing cardiovascular disease and overweight or obesity but no diabetes saw a 20% relative reduction in major adverse cardiovascular events. SELECT is the trial to know if you do not have diabetes, because that is the population it enrolled. Dulaglutide showed benefit in REWIND . And the tablet form of semaglutide showed a 14% reduction in the same composite outcome in SOUL, published in 2025.
Tirzepatide sits in a different position, and the distinction is worth understanding. SURPASS-CVOT enrolled more than 13,000 adults with type 2 diabetes and cardiovascular disease, and compared tirzepatide against dulaglutide rather than against placebo. It met its goal of non-inferiority. Tirzepatide holds its own against an agent that already has proven benefit, which is reassuring. It is not the same evidence as a placebo-controlled demonstration of reduced events.
So the medicine that performed better on weight in head-to-head testing is not the one carrying placebo-controlled proof of reduced cardiovascular events. Those are two separate questions, and for anyone with existing heart disease, the second may weigh more heavily than the first.
This is the kind of trade-off that belongs in a conversation with a doctor who knows your history, not in an article, and certainly not in a comparison chart.
Were people like you in any of these trials?
Mostly, no. This is the part almost every article on this topic leaves out, and it is the part that matters most to an Indian reader.
A systematic review and meta-analysis published in BMJ Global Health examined participation across the multicentre randomised trials of GLP-1 medicines for obesity. Western participants made up 79% of enrollment. Asians made up 13%. African-American participants made up 9%.
The deeper problem is what sits underneath that 13%. “Asian” in these trials bundles together East Asian, Southeast Asian and South Asian participants, groups with meaningfully different body composition and metabolic risk. South Asians were not reported as a separate category, so nobody can say from the published record how many Indians were studied or how they responded. Individual trials show the same skew: in STEP-5 , 93.1% of participants were western.
Why this is not a technicality. Indian bodies accumulate fat differently. At any given BMI, Indian adults tend to carry more visceral fat, less muscle, and more insulin resistance than European adults, a pattern clinicians call the thin-fat phenotype. Consequences arrive earlier and at lower weights.
Indian clinical thresholds reflect this. The revised definition of obesity for Asian Indians, published in 2025 after fifteen years without an update, sets increased adiposity at a BMI above 23 and abandons the term overweight entirely, replacing it with a two-stage system built around abdominal fat and organ impact. Abdominal obesity is marked at a waist above 90 cm in men and 80 cm in women. The Western trials that generated the efficacy figures used entry criteria of BMI 27 or 30.
The scale of the gap is not small. The ICMR-INDIAB national study found generalised obesity in 28.6% of Indian adults and abdominal obesity in 39.5%, alongside diabetes in 11.4%. A population with that profile was largely absent from the trials that define how these medicines are understood.
Be careful about what this does and does not mean. It is an evidence gap, not evidence of a different effect. There is no good data showing these medicines work worse in Indians. There is simply very little data showing what they do in Indians specifically, and a recent review of obesity management in South Asians makes the same point about the whole field. Anyone who tells you confidently how a GLP-1 medicine behaves in an Indian body is going beyond what has been published.
What side effects should you genuinely expect?
Gastrointestinal, common, and concentrated early. Nausea is the one most people meet first. Vomiting, diarrhea, constipation, reflux and burping follow in frequency. Across the trials these were mostly mild to moderate, clustered during the period when the dose was being stepped up, and eased as the body adjusted.
The word “mostly” carries weight there. In SELECT, gastrointestinal effects drove 16.6% of the treatment group to stop the medicine permanently, against 8.2% of the placebo group. In SURMOUNT-5, discontinuation for gastrointestinal reasons ran at 5.6% and 2.7% in the two arms. So this is not a fringe experience, and it is also not the majority experience.
Slowed gastric emptying interacts badly with heavy, oily and late meals, and the standard Indian dinner timing sits later than the Western pattern these medicines were studied in. Reflux and nausea often track the evening meal more closely than the dose.
Fatigue, headache and dizziness are reported and usually reflect the drop in food intake rather than a direct drug effect. Gallbladder problems, including stones, appear more often with rapid weight reduction generally, whatever causes it.
What about the rare risks you keep reading about?
Four come up repeatedly. Each deserves a straight answer rather than reassurance or alarm.
Thyroid tumours
Several medicines in this class carry a boxed warning for thyroid C-cell tumours. That is the warning category regulators apply to serious risks, and it sits at the top of the prescribing information. The prescribing information states the basis plainly: rodents given semaglutide developed these tumours, and whether that translates to humans has not been determined. Long-term human trial data has not shown a signal. The medicines are contraindicated outright in anyone with a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN 2, and that is a question worth asking your family before you start rather than after.
Pancreatitis
Listed as a warning on the labels. Cases have been reported after marketing. Whether the class causes pancreatitis at a rate above background remains genuinely unsettled in the literature. Severe, persistent abdominal pain radiating to the back is the symptom that means stopping and seeking care the same day.
Vision loss
This one is newer. In June 2025, after reviewing trial data, post-marketing reports and the published literature, the European regulator concluded that a form of optic nerve damage called NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking it. The World Health Organization issued a matching alert the same month. The vision loss is typically sudden, painless, in one eye, and generally not reversible. Sudden visual change on this medicine is an immediate call to a doctor, not a wait-and-see.
Muscle loss
Real, quantified, and covered in the next section because it deserves more than a line.
Are you losing muscle along with the fat?
Yes, and the honest answer is that the size of the effect is contested.
A review published in Diabetes, Obesity and Metabolism pulled the body-composition substudies together. In STEP-1, the fraction of weight lost that came from lean mass worked out to roughly 45%. In SURMOUNT-1, it was closer to 26%. Across the wider literature the range runs from about 20% to 50%.
Two things pull that number down. Some lean mass loss is obligatory: fat tissue itself contains non-fat components that disappear along with the fat, and correcting for this lowers the semaglutide figure toward 30%. And these proportions are broadly in line with what happens during weight loss from eating changes alone or after bariatric surgery. Losing some muscle while losing weight is not unique to this class of medicine.
Here is why it still lands harder in an Indian context. If you start with less muscle at a given BMI, which is the thin-fat pattern, then losing a quarter to a third of your weight loss as lean tissue takes a bigger bite out of a smaller reserve. The Indian obesity guidance published in 2025 flags exactly this, raising sarcopenia as a risk of weight-loss treatment and pointing to higher protein intake and resistance training as the counterweights.
That is a matter for a doctor and a qualified dietician who can look at your intake and your training, not something to self-prescribe off an article.
What is the facial change people call “Ozempic face”?
It is not a drug effect. It is a weight-loss effect that got a brand name attached to it.
The face carries discrete fat pads that give the cheeks and temples their volume. Lose weight quickly and those pads shrink along with everything else, leaving skin that has not had time to retract. The result reads as hollowing, sharper lines and a more aged appearance. Rapid weight loss by any route does this. Bariatric surgery does it. Aggressive dieting does it.
What the medicines changed is the speed and the scale, which made the effect visible enough to name. Older adults notice it more, because skin elasticity declines with age.
Does it matter whether it is an injection or a tablet?
For most of the class, injection is the only option. Semaglutide is the exception, available both as an injection and as a tablet.
The tablet is not a lesser version in terms of cardiovascular evidence. SOUL enrolled 9,650 adults with type 2 diabetes and either established cardiovascular disease or kidney disease, and found a 14% reduction in major adverse cardiovascular events against placebo. That is a meaningful result for anyone who will not use a needle.
The trade-off is absorption. Oral semaglutide is a peptide, which the digestive system is designed to destroy, so it is formulated with an absorption enhancer and comes with strict instructions about when and how it is taken relative to food and other medicines. Get that wrong and the dose does not reach the bloodstream. Adherence is a real clinical variable here in a way it is not with a weekly injection.
Frequency also varies across the class. Some members are taken daily, some weekly, and one older member was taken twice daily. Which rhythm suits a person is a genuine part of the choice.
India now has many versions of these medicines. Does that change anything?
It changes availability and it introduces a distinction that Western coverage of this topic will actively mislead you about.
The core Indian patent on semaglutide expired in March 2026. Within weeks, more than forty branded versions from Indian manufacturers had entered the market, each cleared by the Drugs Controller General of India.
A regulator-approved generic contains the same molecule, made to the same standard, assessed by the same authority. It is a different category of product from what most American articles mean when they warn about “compounded semaglutide”, which refers to preparations made outside the normal approval pathway during a supply shortage. Applying that warning to an approved Indian generic is a category error.
The genuine risk in this market is elsewhere: falsified product. The World Health Organization has warned about counterfeit versions of these medicines circulating internationally. Anything sourced outside a licensed pharmacy against a valid prescription sits outside every safety assurance described in this article.
Every medicine discussed here is prescription-only in India. That is not a formality. It is the mechanism by which the contraindications in the next section actually get checked.
Who should not be taking these at all?
The absolute exclusions are narrow and firm. A personal or family history of medullary thyroid carcinoma rules these medicines out, as does the inherited syndrome MEN2. So does a previous serious allergic reaction to the molecule.
Pregnancy and breastfeeding rule them out, and anyone planning a pregnancy needs to raise the timing well in advance.
Then there is a wider group where the answer is caution rather than prohibition: a history of pancreatitis, significant gastrointestinal disease including gastroparesis, active gallbladder disease, advanced kidney disease, and existing diabetic eye disease, which needs monitoring because rapid improvement in blood sugar can temporarily worsen it. Anyone already taking insulin or a sulfonylurea needs those doses reviewed, because the combination can drive blood sugar too low.
None of that is a checklist you can run on yourself. It is the reason these medicines are prescription-only.
What happens the day you stop?
Appetite returns. The mechanism only works while the medicine is present, and when it clears, hunger signalling reverts to where it was.
Weight regain after stopping is the pattern across the trial evidence, not the exception. This is the single most important thing to understand before starting, and it is the thing most conversations about these medicines skip.
There is a second-order concern here that connects back to the muscle question. Weight lost and then regained does not return in the same proportions. Fat tends to come back faster than lean tissue. Repeated cycles of loss and regain can therefore shift body composition unfavourably over time, which is a particular concern for anyone starting with limited muscle reserve.
That is the argument for treating obesity as a long-term condition rather than a course of treatment, and for building the eating and training changes during the period when appetite is easiest to manage rather than after.
| The Bottom Line |
| These medicines work, the differences within the class are real, and neither of those facts settles which one suits a given person. The dual-receptor option produced the larger reduction in the one head-to-head trial. The single-hormone injectable has placebo-controlled evidence of reduced cardiovascular events, which the dual-receptor option does not yet have. Those are two different questions, and they can point in different directions. The honest limitation is the evidence base. It was built overwhelmingly in Western populations, at BMI thresholds that do not describe Indian risk, in bodies that do not carry fat the way Indian bodies do. That does not make the medicines wrong for Indian users. It means the confident numbers you read were measured somewhere else. Every medicine here is prescription-only, and the decision belongs with a doctor who can weigh your history, your heart, your thyroid, your kidneys and your muscle mass against what these medicines actually do. |
Frequently asked questions
Is a GLP-1 medicine the same thing as insulin?
No. Insulin is a hormone that directly lowers blood glucose and can push it too low. GLP-1 medicines prompt your own pancreas to release insulin, but only when glucose is already high, which is why used on their own they carry a low risk of hypoglycaemia. They are different classes with different mechanisms and different risks.
How long does the nausea last?
For most people it concentrates in the weeks when the dose is being increased and settles as the body adapts. It is not universal and it is not permanent for most who get it. If it is severe, persistent, or accompanied by intense abdominal pain, that is a reason to contact your doctor rather than to wait it out.
Do these medicines cause thyroid cancer?
The boxed warning comes from rodent studies, and regulators have been explicit that whether the finding applies to humans has not been determined. Long-term human trials have not shown an increase. The firm rule is different: anyone with a personal or family history of medullary thyroid carcinoma, or the MEN2 syndrome, should not take them at all.
Can I switch from one GLP-1 medicine to another?
Switching happens in clinical practice, for tolerability or for effect. It is not something to attempt independently, because the dose relationships between different molecules are not straightforward and restarting at the wrong point can bring the early side effects back in force. This is a prescriber decision.
Do these medicines work differently in Indian bodies?
Nobody can answer that from the published evidence, and that is the honest answer. South Asians were not reported as a distinct group in the trials that established how these medicines perform. What is known is that Indian adults develop metabolic complications at lower BMI and waist measurements than Western populations, which means the eligibility thresholds used in those trials do not describe Indian risk well.
| Medical Disclaimer |
| This article is educational and is not medical advice. It does not recommend, promote or endorse any specific medicine, brand or manufacturer, and it is not a substitute for consultation with a registered medical practitioner. All medicines discussed are prescription-only in India and must be prescribed and supervised by a qualified doctor who has assessed you personally. Do not start, stop or change any prescription medicine on the basis of this article. If you experience sudden vision change, severe abdominal pain, or any symptom that concerns you while taking these medicines, seek medical attention without delay. |
